Thabo Tselane

Group Managing Director, NTP Radioisotopes

Thabo Tselane is Group Managing Director of NTP Radioisotopes.

NTP Radioisotopes is the Necsa subsidiary that produces molybdenum-99, iodine-131 and lutetium-177 for nuclear medicine, supplying customers in nearly 60 countries. In 2024/25 the NTP Group earned revenue of R1.57 billion and net profit after tax of R118.3 million.

In the job

  1. NTP recorded one million disabling-injury-free hours worked, and its safety culture survey score rose from 3.55 to 4.00 during 2024/25. Source

  2. NTP reported a 2.6-fold rise in lutetium-177 sales volumes in 2024/25, with revenue growth in Europe and South America. Source

Career before

  1. Manager, DPI-Fike Plastics
  2. General manager, BKS Consulting Engineers, Rustenburg
  3. Senior executive manager, Nuclear Compliance Assurance and Enforcement, National Nuclear Regulator
  4. Interim chief executive officer, National Nuclear Regulator
  5. from March 2014Divisional executive, Nuclear Operations, Necsa
  6. Acting managing director, NTP Radioisotopes

Education

MSc in Nuclear Physics, University of the Western Cape; Senior Management Programme, University of Pretoria; Global Development Management Programme, Gordon Institute of Business Science

Sources

  1. ntp.co.za
  2. ntp.co.za
  3. necsa.co.za
  4. africasciencediplomacy.org
  5. static.pmg.org.za

Facts last checked 3 November 2026. Spotted something out of date? Tell us.

More profiles

All profiles
Pharmaceuticals Andy Hall Chief Executive Officer, Adcock Ingram Since 2015
Pharmaceuticals Joanna Johnston Country President, Novartis South Africa
Pharmaceuticals Morena Makhoana Chief Executive Officer, Biovac
Pharmaceuticals Paul Miller Chief Executive Officer, Cipla Africa, Cipla South Africa